FDA Alert: Fondaparinux Sodium Shortage & Discontinuation

FDA Drug Shortage Alert: Fondaparinux Sodium Injection Being Discontinued

Fresenius Kabi has notified FDA of its decision to permanently discontinue fondaparinux sodium injection (Arixtra), with all remaining stock expected to deplete by March 2025. The discontinuation of the only FDA-approved generic version leaves Mylan Pharmaceuticals' branded product as the sole domestic supplier of this critical anticoagulant used primarily in orthopedic surgery and deep vein thrombosis prophylaxis.

Regulatory Context

FDA maintains the Drug Shortages Database under authority granted by the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 and expanded by the FDA Reauthorization Act of 2017. Manufacturers must notify FDA at least six months before discontinuing a drug if it is "life-supporting, life-sustaining, or intended for use in emergency medical care" under 21 U.S.C. § 356c. Fondaparinux sodium injection meets this threshold as a medically necessary anticoagulant with limited therapeutic alternatives.

Fresenius Kabi submitted its discontinuation notice in September 2024, citing business decisions rather than manufacturing quality issues or supply chain disruptions. FDA added fondaparinux sodium injection to the Drug Shortages Database on November 14, 2024, with a current status of "discontinued" for the Fresenius Kabi product. The agency has not invoked shortage mitigation measures such as temporary importation or expedited approval of alternative presentations.

Supply Chain Impact

The discontinuation creates three immediate operational challenges for wholesale drug distributors:

Inventory allocation shifts. Remaining Fresenius Kabi stock will flow through existing distribution channels until March 2025 depletion. Distributors holding inventory must implement allocation protocols to prevent stockpiling by individual accounts. Under DSCSA requirements (21 U.S.C. § 360eee), distributors must maintain transaction documentation for all product transfers during this allocation period, with particular attention to suspicious order monitoring under 21 CFR 1301.74(b).

Single-source dependency. Mylan Pharmaceuticals becomes the sole domestic supplier. Wholesale drug distributors sourcing fondaparinux must verify Mylan's manufacturing capacity and distribution network can absorb demand previously met by Fresenius Kabi. This creates concentration risk in trading partner networks — if Mylan experiences manufacturing delays or quality holds, no immediate backup supplier exists in the U.S. market.

Formulary disruption for specialty pharmacies. Fondaparinux is primarily dispensed through specialty pharmacy channels serving orthopedic and hematology patient populations. Specialty pharmacies typically maintain 30-45 day inventory levels for anticoagulants due to cold chain requirements (2-8°C storage). The Fresenius Kabi discontinuation forces immediate formulary review and potential therapeutic substitution protocols, which must be coordinated between specialty pharmacy operations teams, prescribers, and payer medical directors.

Distributor Due Diligence Considerations

Wholesale drug distributors should verify Mylan's current regulatory standing before expanding sourcing relationships. Key verification points:

• FDA establishment registration status: Mylan's manufacturing facilities must hold active FDA establishment registrations under 21 CFR 207. Registration data is publicly searchable via FDA's Establishment Registration & Device Listing system.
• State wholesale drug distributor licenses: Distributors receiving product from Mylan or its authorized distributors should confirm all trading partners hold active state licenses in relevant jurisdictions. Cross-reference against state board of pharmacy databases.
• NABP accreditation: While not required, NABP Accredited Digital Pharmacy or DSCSA Compliance accreditation provides additional verification of trading partner legitimacy.

FDA has not issued guidance on therapeutic substitution protocols for fondaparinux. Distributors should not interpret this shortage as authorization to source non-FDA-approved versions from international suppliers without specific FDA guidance permitting temporary importation.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors and 3PLs tracked in ColdChainCheck's directory, 1,234 hold active FDA establishment registrations — the baseline credential for lawful distribution of fondaparinux sodium injection. However, the average compliance score of 51/100 indicates that fewer than half of tracked entities maintain verification across all six compliance dimensions (state licensure, NABP accreditation, FDA registration, recall history, warning letters, and enforcement actions).

The fondaparinux shortage exposes a gap in specialty pharmacy trading partner networks: only 63 entities in the directory hold NABP accreditation (formerly VAWD), representing less than 5% of tracked distributors. For anticoagulant products requiring cold chain management, NABP accreditation provides independent verification of temperature-controlled storage and handling protocols — a critical signal when consolidating sourcing to a single manufacturer.

The compliance score distribution reveals that 919 entities (72%) fall into the "Fair" tier (26-50 points), meaning they have verified credentials in some but not all jurisdictions. For QA managers expanding their Mylan-authorized distributor network to compensate for Fresenius Kabi's exit, this distribution suggests significant variance in compliance posture across potential trading partners.

Recommended Actions for Compliance Officers

• Verify Mylan-authorized distributors: Cross-reference your current fondaparinux suppliers against the ColdChainCheck directory to confirm active FDA registration and state licensure. Search by entity name or NABP number. Entities scoring below 40/100 warrant additional due diligence before increasing purchase volumes.

• Assess cold chain capability: For fondaparinux (2-8°C storage), prioritize distributors with NABP accreditation or documented cGMP compliance. Filter the directory for NABP-accredited entities and verify their coverage in your service states.

• Monitor recall history: 73 entities in the directory have at least one FDA recall on record. Before onboarding new Mylan distributors, check their enforcement history. A clean record over the past 24 months is a stronger compliance signal than relying solely on self-reported certifications.

• Document sourcing changes: Under DSCSA transaction history requirements (21 U.S.C. § 360eee-1(c)), maintain records of all trading partner verifications conducted during this supply transition. If Mylan experiences a shortage or quality hold, your audit trail must demonstrate proactive due diligence.

ColdChainCheck tracks FDA drug shortage alerts and updates entity compliance scores as new enforcement data becomes available. See the Regulatory Guides section for coverage of DSCSA wholesale distributor requirements and trading partner verification protocols.

Disclaimer: This article is provided for informational purposes only and does not constitute legal, regulatory, or professional advice. Verify all compliance statuses independently with the relevant regulatory authority before making sourcing or vendor qualification decisions.